Results 131 to 140 of about 23,315 (198)

Medicinal Chemistry Review of the NEET Protein Family. [PDF]

ChemMedChem
Geldenhuys WJ, Mersch J, Cicala D, Sarker R, Roknuzzaman ASM, Maghareh M, Carerra EM, Lade DM, Menze MA, Konkle ME, Huber JD.   +10 more
europepmc   +1 more source

Comparative Evaluation of Quercetin, Pioglitazone, Insulin, and Novel 5-Chromenyl-Methylene Thiazolidinedione Derivative on Nerve Function in Experimental Diabetic Peripheral Neuropathy. [PDF]

Biomedicines
Haranguș A, Chiș IC, Clichici SV, Coadă CA, Moldovan R, Moldovan C, Ciocoi-Pop RD, Toader A, Lele L, Mocan T.   +9 more
europepmc   +1 more source

Fluid retention versus cardio protection: rethinking pioglitazone. [PDF]

Ann Med Surg (Lond)
Imran G, Ali U, Mahato RK.
europepmc   +1 more source

Personalized Diabetes Therapy Part 2-Individual Diabetes Treatment (Standard of Care Plus, SOC+). [PDF]

J Pers Med
Jantz J, Pfützner A.
europepmc   +1 more source

Comparative Efficacy of Pioglitazone, Saroglitazar, and Silymarin on Biochemical and Histopathological Hepatic Outcomes in a Wistar Rat Model of Non-alcoholic Fatty Liver Disease and Their Correlation With Insulin Sensitivity. [PDF]

Cureus
Jain I, Nath R, Kumar M, Pal R, Dixit R.
europepmc   +1 more source

Observational studies on the association of outpatient antidiabetic medication use and COVID-19 outcomes: are the findings more relevant to diabetes management than to COVID-19 pathology? A mini-review. [PDF]

Front Clin Diabetes Healthc
Dimnjaković J, Buble T, Brborović O.
europepmc   +1 more source

Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells. [PDF]

Ann Hematol
Atef B, El-Ashwah S, Saleh LM, Gawish H, Mabed M.   +4 more
europepmc   +1 more source

PPAR-γ activation by pioglitazone inhibits microglia-mediated neuroinflammation and alleviates disease in neuromyelitis optica spectrum disorders. [PDF]

Acta Neuropathol Commun
Yick LW, Chan EYY, Zou W, Yau KX, Kwan JSC, Lee CY, Chan KH.   +6 more
europepmc   +1 more source

Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasias. [PDF]

Front Pharmacol
Harrer DC, Lüke F, Pukrop T, Ghibelli L, Reichle A, Heudobler D.   +5 more
europepmc   +1 more source

Drug-drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors. [PDF]

Cancer Chemother Pharmacol
Katsuya Y, Takenaka S, Takahashi S, Yamamoto N.   +3 more
europepmc   +1 more source